Abstract
This article considered already existing studies about Deep Brain Stimulation in Mood and Anxiety Disorders. In particular, articles regarding Obsessive-Compulsive Disorder and Major Depression were mostly analyzed, due to the lack of researches about other types of Mood and Anxiety Disorders. We have concentrated on the target areas where Deep Brain Stimulation was most commonly applied, and on the effects this measure had on treatment-refractory patients. The obtained results showed that the stimulation of the: nucleus accumbens, subgenual cingulate cortex and ventral capsule/ventral striatum, has a positive influence on the development of the disorders investigated, sometimes showing the complete remission of the symptoms. Although Deep Brain Stimulation was overall found to be a promising and safe treatment for Mood and Anxiety Disorders, there are not enough studies proving its efficacy in wide samples and in the presence of more complex variables.
Keywords: Anxiety disorder, deep brain stimulation, depression, obsessive compulsive disorder.
CNS & Neurological Disorders - Drug Targets
Title:Deep Brain Stimulation: A New Treatment in Mood and Anxiety Disorders
Volume: 13 Issue: 6
Author(s): Bruna Velasques, Claudia Diniz, Silmar Teixeira, Consuelo Cartier, Caroline Peressutti, Farmy Silva, Marcele de Carvalho, Aline Novaes, Juliana Bittencourt, Antonio Egidio Nardi, Elie Cheniaux, Luis Basile, Mauricio Cagy, Roberto Piedade and Pedro Ribeiro
Affiliation:
Keywords: Anxiety disorder, deep brain stimulation, depression, obsessive compulsive disorder.
Abstract: This article considered already existing studies about Deep Brain Stimulation in Mood and Anxiety Disorders. In particular, articles regarding Obsessive-Compulsive Disorder and Major Depression were mostly analyzed, due to the lack of researches about other types of Mood and Anxiety Disorders. We have concentrated on the target areas where Deep Brain Stimulation was most commonly applied, and on the effects this measure had on treatment-refractory patients. The obtained results showed that the stimulation of the: nucleus accumbens, subgenual cingulate cortex and ventral capsule/ventral striatum, has a positive influence on the development of the disorders investigated, sometimes showing the complete remission of the symptoms. Although Deep Brain Stimulation was overall found to be a promising and safe treatment for Mood and Anxiety Disorders, there are not enough studies proving its efficacy in wide samples and in the presence of more complex variables.
Export Options
About this article
Cite this article as:
Velasques Bruna, Diniz Claudia, Teixeira Silmar, Cartier Consuelo, Peressutti Caroline, Silva Farmy, Carvalho de Marcele, Novaes Aline, Bittencourt Juliana, Nardi Egidio Antonio, Cheniaux Elie, Basile Luis, Cagy Mauricio, Piedade Roberto and Ribeiro Pedro, Deep Brain Stimulation: A New Treatment in Mood and Anxiety Disorders, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612122929
DOI https://dx.doi.org/10.2174/1871527313666140612122929 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Big Data Mining for CNS Diseases Analysis and Treatment: Focusing on Drug Target Discovery
Central nervous system (CNS) diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, represent a major global health challenge. Despite significant research efforts, the complexity and multifactorial nature of these diseases hinder the development of effective treatments. The rise of big data analytics and high-throughput technologies ...read more
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently, there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system and neurological disorders. The purpose ...read more
Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies
Demyelinating disorders, particularly multiple sclerosis represent chronic disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. This thematic issue will present a comprehensive overview of novel therapeutic advances targeting these processes. In addition to dissecting the roles of innate versus adaptive immunity, antibody therapies, and tyrosine kinase ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies
Current Neuropharmacology Antiepileptogenic Effect of Retinoic Acid
Current Neuropharmacology Identification of Attention Deficit/Hyperactivity Disorder in Children Using Multiple ERP Features
Current Bioinformatics Study of the Effects of L-tryptophane Nanoparticles on Motor Behavior in Alzheimer's Experimental Models
CNS & Neurological Disorders - Drug Targets Cytosolic Oligopeptidases: Features and Possible Physiopathological Roles in the Immune and Nervous Systems
Current Medicinal Chemistry - Central Nervous System Agents Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2
Current Neurovascular Research Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis
Current Pharmaceutical Design On the Biomaterials for Nanostructured Ocular Therapeutics
Current Organic Chemistry Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Effect of Exercise on Dual-task and Balance on Elderly in Multiple Disease Conditions
Current Aging Science Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets The Use of Nanotechnology in Cosmetic Formulations: The Influence of Vehicle in the Vitamin A Skin Penetration
Current Nanoscience Immunometabolism Dysfunction in the Pathophysiology and Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry NMR Screening and Hit Validation in Fragment Based Drug Discovery
Current Topics in Medicinal Chemistry Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry ‘Hot’ Cognition in Major Depressive Disorder: A Systematic Review
CNS & Neurological Disorders - Drug Targets Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Nanostructured Lipid Carriers: A Novel Platform in the Formulation of Targeted Drug Delivery Systems
Current Nanomedicine